B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 190.05 DKK -4.11% Market Closed
Market Cap: 14.9B DKK
Have any thoughts about
Bavarian Nordic A/S?
Write Note

Bavarian Nordic A/S
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bavarian Nordic A/S
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
B
Bavarian Nordic A/S
CSE:BAVA
Research & Development
-kr1.3B
CAGR 3-Years
-58%
CAGR 5-Years
-27%
CAGR 10-Years
-12%
Genmab A/S
CSE:GMAB
Research & Development
-kr8.8B
CAGR 3-Years
-75%
CAGR 5-Years
-36%
CAGR 10-Years
-32%
Zealand Pharma A/S
CSE:ZEAL
Research & Development
-kr856.1m
CAGR 3-Years
-26%
CAGR 5-Years
-10%
CAGR 10-Years
-18%
Ascendis Pharma A/S
NASDAQ:ASND
Research & Development
-€311.7m
CAGR 3-Years
-1%
CAGR 5-Years
-12%
CAGR 10-Years
-36%
F
Fluoguide AS
STO:FLUO
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Research & Development
-kr24m
CAGR 3-Years
2%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
No Stocks Found

Bavarian Nordic A/S
Glance View

Market Cap
14.8B DKK
Industry
Biotechnology

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The firm is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

BAVA Intrinsic Value
169.64 DKK
Overvaluation 11%
Intrinsic Value
Price
B

See Also

What is Bavarian Nordic A/S's Research & Development?
Research & Development
-1.3B DKK

Based on the financial report for Jun 30, 2024, Bavarian Nordic A/S's Research & Development amounts to -1.3B DKK.

What is Bavarian Nordic A/S's Research & Development growth rate?
Research & Development CAGR 10Y
-12%

Over the last year, the Research & Development growth was 25%. The average annual Research & Development growth rates for Bavarian Nordic A/S have been -58% over the past three years , -27% over the past five years , and -12% over the past ten years .

Back to Top